Table 3 Influence of dorzolamide on retrobulbar hemodynamics. Ocular perfusion in the dorzolamide group. CDI measurements obtained from the patient group treated with dorzolamide (n = 12). The time period between between first and second measurement was 3–5 weeks. Data are given as mean ± standard deviation. Bold printed measures were subjected to statistical testing; all other parameters were observational only.

OA

before dorzolamide

29.6 ± 1.2

3.3 ± 0.4

0.89 ± 0.02

2.82 ± 0.25

after dorzolamide

37.2 ± 3.5

4.4 ± 0.7

0.88 ± 0.02

2.64 ± 0.20

CRA

before dorzolamide

7.3 ± 0.8

1.4 ± 0.1

0.80 ± 0.02

1.98 ± 0.18

after dorzolamide

8.5 ± 0.8

1.8 ± 0.2

0.78 ± 0.02

1.97 ± 0.24

SPCA

before dorzolamide

8.5 ± 0.8

1.9 ± 0.2

0.77 ± 0.02

1.79 ± 0.11

after dorzolamide

12.8 ± 1.4 *

2.2 ± 0.2

0.80 ± 0.03

1.91 ± 0.13

LPCA

before dorzolamide

10.9 ± 0.8

2.0 ± 0.3

0.73 ± 0.07

1.80 ± 0.22

after dorzolamide

16.9 ± 1.7

2.9 ± 0.3

0.83 ± 0.01

1.95 ± 0.12